12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Onglyza saxagliptin regulatory update

Otsuka and Kyowa Hakko Kirin said Japan approved Onglyza saxagliptin to treat Type II diabetes. Kyowa has exclusive, Japanese rights to develop and commercialize saxagliptin under a June 2012 deal (see BioCentury, July...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >